The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant Supplement, 2020Developing Biosignatures for Parkinson's Disease Using Sense of Smell (Supplement)
Study Rationale:
It has been described that people with Parkinson’s disease have a specific signature odor. This odor arises from an oily skin secretion called sebum. Odor detection in the nose is... -
Priority Biology, 2021Developing New Therapeutic Drugs for Parkinson’s in Human Stem Cell Neurons
Study Rationale:
Neurons derived from stem cells from people with Parkinson’s disease offer an opportunity to perform drug and target discovery. We completed a screen of 4,000 drug compounds in such... -
Research Grant, 2020Studying the Effects of TMEM175 and CTSB on Glucocerebrosidase Activity and Alpha-synuclein Properties
Promising Outcomes of Original Grant:
The aim of the original grant was to study if there are genes that modify the risk of Parkinson’s disease (PD) or the age at onset of PD, among people who carry... -
Priority Biology, 2020Effects of LRRK2 Variants on GCase Activity in iPSC-derived Dopamine Neurons and Microglia
Study Rationale:
There is contradictory evidence on whether the LRRK2 and GBA genes, and the proteins that they encode, interact in their effects on Parkinson’s disease. Some studies suggest that... -
Research Grant, 2020Revisiting Alpha-synuclein Pathology Staging and Detection Using an Expanded Antibodies Toolset
Study Rationale:
The levels of alpha-synuclein aggregates and their spreading to different brain region seem to correlate with Parkinson’s disease (PD) progression and symptoms. Increasing evidence... -
Priority Biology, 2020Structural Insights into Activated Intermediates of Parkin Continued
Study Rationale:
Loss of proteins responsible for removing damaged mitochondria (the cell power plants) is the most common cause of young-onset Parkinson’s disease (YOPD). Parkin and PINK1 are key...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.